Concepedia

David Hreniuk

DH

Statistics

Publications

22

Citations

1.4K

H-Index

17

Active since

1989

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Novartis (Switzerland)

Johnson University

Rutgers, The State University of New Jersey

Covance (United States)

David Hreniuk is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in life sciences, pharmacology, and cell biology.

Publications per year

1989–2014

22

Publications

22

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

Kelem Kassahun, Ian McIntosh, Donghui Cui et al. · Drug Metabolism and Disposition · 2007 · 275 citations

, , +16

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

DM Bloomfield, JT Kost, Kalyan Ghosh et al. · Clinical Pharmacology & Therapeutics · 2008 · 151 citations

, , +15

Hydroperoxide-induced oxidative stress impairs heart muscle cell carbohydrate metabolism

David R. Janero, David Hreniuk, H. Sharif · American Journal of Physiology-Cell Physiology · 1994 · 130 citations

, , +17

Inhibition of C-Jun N-Terminal Kinase 1, but Not c-Jun N-Terminal Kinase 2, Suppresses Apoptosis Induced by Ischemia/Reoxygenation in Rat Cardiac Myocytes

David Hreniuk, Michele Garay, William A. Gaarde et al. · Molecular Pharmacology · 2001 · 117 citations

, , +15

Hydrogen peroxide‐induced oxidative stress to the mammalian heart‐muscle cell (cardiomyocyte): Lethal peroxidative membrane injury

David R. Janero, David Hreniuk, H. Sharif · Journal of Cellular Physiology · 1991 · 110 citations

, , +17

1–5 of 22